Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)

NCT02233504 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

High Risk MDS or AML Patients

Interventions

DRUG: Exjade® (deferasirox, ICL670)

Sponsor

Abramson Cancer Center at Penn Medicine